Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05159518 | A Study of PRT2527 in Participants With Advanced Solid Tumors | PHASE1 | COMPLETED | 30 | — | — | Feb 14, 2022 | Dec 6, 2023 | Dec 11, 2023 | 8 | United States |
Dose limiting toxicities will be evaluated over the 21-day observation period
The MTD will be established for further investigation in participants with advanced solid tumors
The RP2D will be established for further investigation in participants with advanced solid tumors
| Arm | Type | Description |
|---|---|---|
| PRT2527 | EXPERIMENTAL | PRT2527 will be administered by intravenous infusion |
| Name | Type | Description |
|---|---|---|
| PRT2527 | DRUG | PRT2527 will be administered by intravenous infusion |
Inclusion Criteria: * Tumor types under study 1. Selected sarcomas with a documented gene fusion 2. Castrate resistant prostate cancer (CRPC) 3. Hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer 4. Non-small cell lung cancer (NSCLC) 5. MYC amplified solid tumors * Must...